Skip to main content
Menu
search

Cell Therapy Facility for DTM at NIH Clinical Center

Cell Therapy Facility for DTM at NIH Clinical Center

Client:
Department of Transfusion Medicine (DTM)

Completion:
2022

Facility:
Cell Therapy Facility

Application:
Manufacture of Products Used to Test and Treat NIH Clinical Center Patients with Cancer, Haematological Malignancies, Marrow Failure, Congenital Immune Disorders, and Autoimmune Diseases

Location:
Bethesda, MD

Maximizing Available Space While Meeting the Stringent Requirements of cGMP Ceanroom Standards with our Cell Therapy Facility

The Department of Transfusion Medicine (DTM) at NIH required an increase in production capacity for clinical trials, specifically to manufacture products used to test and treat NIH Clinical Center patients with cancer, haematological malignancies, marrow failure, congenital immune disorders, and autoimmune diseases. Germfree was tasked with designing and building a modular cell therapy facility that could meet the stringent requirements of cGMP cleanroom standards while maximizing the available space.
Project features

Size: 6,400 sq. ft.

Layout configurations: 6-module cell therapy facility

Facilities/Equipment: MP cleanroom, support and mechanical space

Features: Full central utility plant on top of the modules to reduce the facility shell building size

The challenge

One of the key features of this cell therapy facility was a full central utility plant on top of the modules. This allowed the NIH to reduce the size of the overall facility shell building, resulting in cost and schedule advantages.

The answer

To meet the needs of our client, we designed and built a 6-module facility with 6,400 sq. ft. of cGMP cleanroom, support, and mechanical space.

How we helped

The modular facility was installed on top of the East Terrace of Building 10 which allowed the NIH to take advantage of space that had poor utilization. The cell therapy facility complies with current Good Manufacturing Practices (cGMP) as they apply to pertain to producing cell therapy products for clinical investigations.

Cell therapy facility details

The DTM cGMP Cell therapy facility is made up of six prefabricated modules, which include four ISO-7 cell processing suites, ISO-7 and ISO-8 cleanroom lab spaces, tissue culture suites, and cold room storage. A second story interstitial level mezzanine provides mechanical equipment to support the facility and Building 10 supplies electrical infrastructure to the facility.

The processing suites are unidirectional flow for personnel, materials, product and waste. Key materials of construction for the cleanroom interior included Arcoplast wall panels for walls and ceilings with coved corners and joints and stainless steel doors. The modular facility including all structures and utilities (MEP) were provided turnkey. The facility was factory built and tested at Germfree in Ormond Beach, FL.

Germfree is proud to have contributed to a critical project that will impact the lives of patients with serious medical conditions. Our team worked closely with our client to develop a customized solution that met their specific needs while adhering to the highest standards of quality and safety. We believe that this project will help to advance the field of cellular therapy and improve patient outcomes, and we are honored to have played a role in making that possible.

This facility was built using Germfree’s proven modular cleanroom platform, click here to learn more about our modular cleanrooms.

DTM Cell Therapy Facility: Gallery

Read about the unique process we used to deliver this project and how we can deliver yours.

Learn about our process

You might also be interested in

Video

An Engineering Perspective: Challenges Associated with Building New Isolator Technology (AST x Germfree)

Paula Rizo, Mechanical Engineering Lead for Equipment, delves into the groundbreaking features of Germfree and AST's latest collaboration.
Video

Kevin Kyle’s Vision: Transforming Industry Standards through Germfree and AST’s Revolutionary Collaboration

Kevin Kyle, Germfree’s CEO, shares the first look at Germfree and AST’s revolutionary collaboration, unveiling a cutting-edge isolator that is set to redefine standards in the pharmaceutical industry.
User gowning in mirror
Articles

Leveraging Current Technology and Regulatory Frameworks to Deliver Patient Access Today

Leveraging Current Technology and Regulatory Frameworks to Deliver Patient Access Today

Contact us: Let's unlock your scientific potential together

Complete our contact form and a member of our commercial team will contact you within 24 hours.

White email icon on a green diamond

Service & support: cs@germfree.com